Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
TH Baryakova, BH Pogostin, R Langer… - Nature Reviews Drug …, 2023 - nature.com
Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …
socioeconomic consequences. Although the underlying reasons are generally understood …
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates
The rule of 5 (Ro5) is a set of in silico guidelines applied to drug discovery to prioritize
compounds with an increased likelihood of high oral absorption. It has been influential in …
compounds with an increased likelihood of high oral absorption. It has been influential in …
[HTML][HTML] Capecitabine and oxaliplatin for advanced esophagogastric cancer
D Cunningham, N Starling, S Rao… - … England Journal of …, 2008 - Mass Medical Soc
Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom, J Verweij, K Nooter… - European journal of …, 2001 - Elsevier
Cremophor EL (CrEL) is a formulation vehicle used for various poorly-water soluble drugs,
including the anticancer agent paclitaxel (Taxol). In contrast to earlier reports, CrEL is not an …
including the anticancer agent paclitaxel (Taxol). In contrast to earlier reports, CrEL is not an …
EGFR antagonists in cancer treatment
F Ciardiello, G Tortora - New England Journal of Medicine, 2008 - Mass Medical Soc
Functional activation of growth factors and receptors of the epidermal growth factor receptor
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic …
MJ Atkinson, A Sinha, SL Hass, SS Colman… - Health and quality of life …, 2004 - Springer
Background The objective of this study was to develop and psychometrically evaluate a
general measure of patients' satisfaction with medication, the Treatment Satisfaction …
general measure of patients' satisfaction with medication, the Treatment Satisfaction …
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves, A Wong, MP Nowacki, M Abt… - … England Journal of …, 2005 - Mass Medical Soc
Background Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant
treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established …
treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established …
Nanomedicine for increasing the oral bioavailability of cancer treatments
Oral administration is an appealing route of delivering cancer treatments. However, the
gastrointestinal tract is characterized by specific and efficient physical, chemical, and …
gastrointestinal tract is characterized by specific and efficient physical, chemical, and …
Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature
D Eek, M Krohe, I Mazar, A Horsfield… - Patient preference …, 2016 - Taylor & Francis
Objective The emergence of various modes of administration for cancer treatment, including
oral administration, brings into focus the importance of patient preference for administration …
oral administration, brings into focus the importance of patient preference for administration …
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a …
PURPOSE: To compare the response rate, efficacy parameters, and toxicity profile of oral
capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line …
capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line …